A Study of Entinostat and FOLFOX in Subjects With Pancreatic Adenocarcinoma
The main purpose of this study is to find the best dose of entinostat when given in combination with FOLFOX for pancreatic cancer.
Pancreas Cancer
DRUG: Entinostat|DRUG: FOLFOX regimen
Dose limiting toxicity (DLT), Dose limiting toxicity (DLT), During the first 28 days of treatment
Incidence, nature and severity of adverse events (AE), Incidence, nature and severity of adverse events (AE), From time of enrollment until completion of the Safety Visit 30 days (+/- 7) days after last dose of entinostat (treatment with entinostat may continue until disease progression, death, unacceptable toxicites or withdrawal, estimated time 6 months)|Progress free survival (PFS), Progress free survival (PFS), From study entry until disease progress or death from any cause, whichever occurs first (assessed at 6 months)|Overall response rate (ORR), Overall response rate (ORR) as defined as proportion of patients with complete response (CR) or partial response (PR), Through study completion, estimated 1 year
The main purpose of this study is to find the best dose of entinostat when given in combination with FOLFOX for pancreatic cancer.